Moderna was No. 1 on CNBC’s Disruptor 50 list in 2015, and five years later it’s still disrupting. The company is the front-runner in the race for a Covid-19 vaccine. The 10-year-old company has managed to leapfrog industry giants and is set to begin a 30,000-person efficacy trial in July, the first planned in the U.S.
Trending:
Moderna CEO sees 'high probability' of success with COVID-19 vaccine